SCHOTT Pharma reported second-quarter fiscal 2026 results and kept its full-year targets intact as it continues to contend with lower polymer syringe demand related to a large glass syringe customer.
For the quarter, the company recorded sales of €247.9 million, a touch higher than the consensus estimate of €246 million. On a constant currency basis, revenue was flat versus the prior year, below analyst expectations for 0.6% growth, and on a reported basis revenue fell 1.8%. High-value solutions made up 55% of the sales mix for the period.
EBITDA for the quarter totaled €64.6 million, slightly under the consensus figure of €65 million, yielding an EBITDA margin of 26.0% compared with an expected 26.4%.
Guidance and segment outlook
SCHOTT Pharma reaffirmed its fiscal 2026 organic, constant currency revenue growth guidance of approximately 2% to 5%. Consensus sits at 3.3%. The company expects the Drug Containment Solutions segment to be the main contributor to sales growth. In contrast, the Drug Delivery Systems segment is anticipated to face headwinds due to a revised demand profile for glass syringes from a significant customer.
Management emphasized that polymer syringe demand remains weak, with declining mRNA volumes cited as a factor weighing on performance.
Margins, capacity and investments
SCHOTT Pharma reiterated an EBITDA margin target for the full year of approximately 27%, marginally below consensus expectations of 27.1%. The company said the margin outlook reflects ongoing product mix pressures and underutilization of Drug Delivery Systems capacity, together with ramp-up costs associated with new manufacturing facilities in Serbia and Hungary.
Management expects the share of high-value solutions to remain at the prior year level of 57% and has projected capital expenditure in the range of €140 million to €160 million for the year.
The company maintained its full-year guidance despite near-term headwinds in its Drug Delivery Systems business and ongoing volatility in syringe demand. The outlook points to growth led by containment solutions while the delivery business contends with customer-adjusted volumes and factory start-up costs.